We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price ...

"It is integrated into everything that we do," says Merck's chief information and digital officer Dave Williams.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

International science and technology firm Merck has announced investment of over £4 million in its Life Science facility in ...

We recently compiled a list of the 8 Best US Stocks For Foreign Investors Right Now. In this article, we are going to take a ...

Empowering young women with the confidence to excel in their education is key to inspiring the next generation' ...

Zacks Research lowered their Q3 2024 earnings estimates for Merck & Co., Inc. in a report issued on Monday, October 21st.

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...